SCHEMBL25354201

SCHEMBL25354201

COCCOCOc1cc(O)c2c(C)cccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
F2 P00734 1/20 0.33
ELANE P08246 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
FFAR1 O14842 1/20 0.32
EGFR P00533 1/20 0.32
ENPP2 Q13822 1/20 0.32
PIK3CD O00329 2/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
PPARA Q07869 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
MIF P14174 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30576965 1.00 CTNNB1 (0.35) CTNNB1HSP90AA1HSP90AB1F2ELANE
SCHEMBL25353794 0.86 CTNNB1 (0.34) CTNNB1HSP90AA1HSP90AB1KDM4EMAPK1
SCHEMBL25354684 0.84 MAPT (0.34) CTNNB1F2ELANEKDM4EMAPK1
SCHEMBL25351792 0.77 PIK3CD (0.30) PIK3CD
SCHEMBL30576889 0.77 PIK3CD (0.30) PIK3CD
SCHEMBL6087766 0.74 CHRNB2 (0.53) CTNNB1MAPK1
SCHEMBL25354760 0.73 L3MBTL1 (0.34) CTNNB1KDM4EMAPK1TDP1PIK3CD
SCHEMBL4599599 0.71 LTA4H (0.48) CTNNB1KDM4E
SCHEMBL29418882 0.71 DAO (0.38) FFAR1EGFR
SCHEMBL23043026 0.71 DAO (0.38) FFAR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154170-A1 FUSED PYRIMIDINES AS KRAS INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2025-05-15 US disclosed
EP-4476221-A1 FUSED PYRIMIDINES AS KRAS INHIBITORS Bayer Aktiengesellschaft (DE) 2024-12-18 EP disclosed
WO-2023152255-A1 FUSED PYRIMIDINES AS KRAS INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 WO disclosed
WO-2023152255-A1 FUSED PYRIMIDINES AS KRAS INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154170-A1 FUSED PYRIMIDINES AS KRAS INHIBITORS KRAS, NRAS, TP53 CTNNB1 915/4885HSP90AA1 3993/4885HSP90AB1 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.